MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

185.02 +2.08 (+1.14%)
Streaming Delayed Price Updated: 10:00 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,002
Open 183.35
Bid (Size) 184.37 (100)
Ask (Size) 185.30 (500)
Prev. Close 182.94
Today's Range 183.25 - 185.80
52wk Range 86.99 - 191.50
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Should You Buy Axsome Therapeutics Stock Before Feb. 23? ↗
The healthcare company is set to release its fourth-quarter results later this month. 
Via The Motley Fool
News headline image
1 High-Flying Stock With More Upside Ahead ↗
Are we witnessing the birth of a biotech giant? 
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
+3.5%
+3.5%
1 Month
+6.1%
+6.1%
3 Month
+34.7%
+34.7%
6 Month
+70.1%
+70.1%
1 Year
+40.6%
+40.6%

More News

Read More
News headline image
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy ↗
Via Chartmill
News headline image
AXSM Stock Rises After Analyst Hikes Price Target On Auvelity Drug Optimism ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗
Via MarketBeat
News headline image
2 Healthcare Stocks to Buy for 2026 and Beyond ↗
Via The Motley Fool
News headline image
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
Via MarketMinute
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 ↗
Via The Motley Fool
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy ↗
Via Stocktwits
News headline image
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
Via The Motley Fool
News headline image
Axsome (AXSM) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSM
From Pomerantz LLP
Via GlobeNewswire
News headline image
2 Monster Stocks in the Making ↗
Via The Motley Fool
News headline image
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Inc (NASDAQ:AXSM) Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗
Via Chartmill

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
What is the current price of Axsome Therapeutics, Inc. - Common Stock?
The current price of Axsome Therapeutics, Inc. - Common Stock is 185.02
When was Axsome Therapeutics, Inc. - Common Stock last traded?
The last trade of Axsome Therapeutics, Inc. - Common Stock was at 02/13/26 10:00 AM ET
What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 8.73B
How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
Axsome Therapeutics, Inc. - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story